Citations

Clear

3042 citation(s) found for "Kumar, S".

A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Bible, Keith C. , Menefee, Michael E., Smallridge, Robert C., Molina, Julian R. , Maples, William J., Karlin, Nina J. , Traynor, Anne M. , Kumar, Priya , Lim, Wan‐Teck , Bossou, Ayoko R., Isham, Crescent R., Webster, Kevin, Kukla, Andrea K., Bieber, Carolyn, Burton, Jill K., Harris, Pamela Jo , Erlichman, Charles , Suman, Vera J. , Goh, Boon Cher

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 7, 2012 | Volume: 97 | Issue: 9 | Pages: 3179-3184

10.1210/jc.2012-1520 | PMID 22774206 Get It

Treatment of Hodgkin's lymphoma in a patient with type III von Willebrand's disease
Kumar, Riten , Rodriguez, Vilmarie , Warad, Deepti , Kumar, Riten

Mayo Clinic

Haemophilia | July 3, 2012 | Volume: 18 | Issue: 5 | Pages: No page available

10.1111/j.1365-2516.2012.02901.x | PMID 22757977 Get It

Abstract 3597: Pazopanib potentiates paclitaxel-induced mitotic catastrophe in association with inhibition of aurora kinases
Isham, Crescent R., Negron, Vivian , Lingle, Wilma L., Fisher, Kelly E., Bible, Keith C. , Kumar, Rakesh

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 3597-3597

10.1158/1538-7445.am2011-3597 Get It

Abstract Background: We recently reported a 49% RECIST response rate in conjunction with a phase 2 clinical trial of the multi-targeted kinase inhibitor pazopanib in differentiated thyroid cancers (DTC; Lancet Oncology 2010, 11:962-72), prompting a search for synergistic pazopanib-containing doublets in thyroid cancer cell lines. Methods and Results: Among all explored pazopanib-containing combinations, paclitaxel and pazopanib produced the greatest combined cytotoxic effects (continuous exposure pazopanib, 24 h paclitaxel; Combination Index, CI, at IC90=0.3). Interestingly, analogous synergy resulted when combining pazopanib with other antimicrotubule agents including other taxanes (docetaxel), Vinca alkyloids (vincristine) and epothilones (ixabepilone) – suggesting a class effect. Further, we found this combination to be synergistic in multiple cancer cell lines including DTC, medullary and anaplastic thyroid cancer lines, and in the A549 lung cancer line. In pursuit of underlying mechanism(s), we noted that the combination produced a greater fraction of cells in G2/M phase of the cell cycle and increased apoptosis in comparison to paclitaxel alone, prompting us to examine whether pazopanib might potentiate the effects of paclitaxel on mitosis. Analysis of cell fate resulting from pazopanib and paclitaxel alone and in combination using time-lapsed video microscopy demonstrated that as low as 2.5 μM pazopanib augmented paclitaxel-induce mitotic catastrophe by 2.4 fold, while inducing no appreciable cell death alone. As pazopanib is somewhat promiscuous in inhibition of kinases, we hypothesized that observed combined effects with antimicrotubule agents might be attributed to its inhibition of cell cycle by targeting CDKs or mitosis by targeting aurora kinases. Inhibition of CDKs 1 and 2 required pazopanib concentrations 1000-times those required to inhibit its primary kinase targets, VEGF-Rs; whereas aurora kinases A and B were inhibited at much lower concentrations (IC50s, 500-1000 nM). Hence, we pursued shRNA aurora A knockdown experiments: potentiation of pazopanib effects were observed in knockdown clones, suggesting that pazopanib single-agent effects are at least in part mediated via aurora A inhibition. Moreover, augmentation of paclitaxel effects were achieved in knockdown clones that rivaled those observed for the pazopanib/paclitaxel combination. Additionally, pazopanib/paclitaxel synergy was reduced in aurora A knockdown clones (CI at IC80: vector<0.5, knockdown clones >1.0), indicating that aurora A inhibition by pazopanib is contributory to paclitaxel/pazopanib synergy. Conclusions: Pazopanib combines with antimicrotubule agents to produce cytotoxic synergy associated with augmentation of mitotic catastrophe that appears at least in part mediated by its ability to inhibit aurora kinases. Supported in part by CA125750. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3597. doi:10.1158/1538-7445.AM2011-3597
Research Resource: Whole Transcriptome RNA Sequencing Detects Multiple 1α,25-Dihydroxyvitamin D3-Sensitive Metabolic Pathways in Developing Zebrafish
Craig, Theodore A., Zhang, Yuji , McNulty, Melissa S. , Middha, Sumit , Ketha, Hemamalini , Magis, Andrew T. , Funk, Cory C. , Price, Nathan D. , Ekker, Stephen C. , Kumar, Rajiv , Singh, Ravinder J. , Price, Nathan D , Ekker, Stephen C , Kumar, Rajiv

Mayo Clinic

Molecular Endocrinology | June 27, 2012 | Volume: 26 | Issue: 9 | Pages: 1630-1642

10.1210/me.2012-1113 | PMID 22734042 Get It

AbstractThe biological role of vitamin D receptors (VDR), which are abundantly expressed in developing zebrafish (Danio rerio) as early as 48 h after fertilization, and before the development of a mineralized skeleton and mature intestine and kidney, is unknown. We probed the role of VDR in developing zebrafish biology by examining changes in expression of RNA by whole transcriptome shotgun sequencing (RNA-seq) in fish treated with picomolar concentrations of the VDR ligand and hormonal form of vitamin D3, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3)].We observed significant changes in RNAs of transcription factors, leptin, peptide hormones, and RNAs encoding proteins of fatty acid, amino acid, xenobiotic metabolism, receptor-activator of NFκB ligand (RANKL), and calcitonin-like ligand receptor pathways. Early highly restricted, and subsequent massive changes in more than 10% of expressed cellular RNA were observed. At days post fertilization (dpf) 2 [24 h 1α,25(OH)2D3-treatment], only four RNAs were differentially expressed (hormone vs. vehicle). On dpf 4 (72 h treatment), 77 RNAs; on dpf 6 (120 h treatment) 1039 RNAs; and on dpf 7 (144 h treatment), 2407 RNAs were differentially expressed in response to 1α,25(OH)2D3. Fewer RNAs (n = 481) were altered in dpf 7 larvae treated for 24 h with 1α,25(OH)2D3vs. those treated with hormone for 144 h. At dpf 7, in 1α,25(OH)2D3-treated larvae, pharyngeal cartilage was larger and mineralization was greater. Changes in expression of RNAs for transcription factors, peptide hormones, and RNAs encoding proteins integral to fatty acid, amino acid, leptin, calcitonin-like ligand receptor, RANKL, and xenobiotic metabolism pathways, demonstrate heretofore unrecognized mechanisms by which 1α,25(OH)2D3 functions in vivo in developing eukaryotes.
Abstract B58: Decreasing the time to activate clinical trials: Initial data from the Multiple Myeloma Research Consortium (MMRC) model
Wear, Sandra, Kelley, Susan L., Quinn-Young, Anne, Kumar, Shaji , Jakubowiak, Andzej, Lonial, Sagar , Anderson, Kenneth C.

Mayo Clinic

Molecular Cancer Therapeutics | June 27, 2012 | Volume: 8 | Issue: 12_Supplement | Pages: B58-B58

10.1158/1535-7163.targ-09-b58 Get It

Abstract Background: Activation of oncology trials is a lengthy and complex process. Recent literature has identified numerous opportunities to improve activation timelines1, 2. The Multiple Myeloma Research Consortium (MMRC) has implemented several processes to identify and overcome myeloma clinical trial activation barriers within the consortium network of 14 North American cancer centers. We examined the impact of these processes preand post- implementation and also compared activation times with published clinical trial metrics data. Methods/Results: 12 MMRC-facilitated trials had sufficient trial data available for review within the study period of May 2006 to March 2009. Activation time was defined as the time from a center's receipt of the final clinical trial protocol from the sponsor, to the time the first patient was enrolled into a trial at any MMRC participating center. The earlier group (EG) of MMRC trials (n=7) required a mean of 257 calendar days for activation, comparable to the mean published data of 251 calendar days1. The more recent group (RG) of MMRC trials (n=5) required a mean of 158 calendar days for activation, representing a 38% shortening of activation time. Additionally, implementation of standardized processes and rigorous project management resulted in a reduction in activation times for all MMRC centers in a given trial from a mean of 7.5 months to a mean of 5.1 months. Improving the mean time of several several specific steps in the process including time to initial protocol review submission from receipt (EG=37 vs. RG=19 days), scientific review committee time (EG=98 vs. RG=55 days), and the time from trial opening to first patient dosed (EG=74 vs. RG=27 days) contributed to the overall decrease in activation times. The EG metrics data are comparable to published data1 for each process step. Conclusion: The MMRC member institutions have seen substantial improvements in trial activation times and are in the process of implementing additional processes to further improve protocol development and trial conduct metrics. The efficiencies and process improvements realized from application of rigorous MMRC project management resources and the standardization of contracting and other key activities may be applied in other areas of oncology clinical trials beyond multiple myeloma. With increasing numbers of new oncology agents to be evaluated and greater pressure on trial sponsors to introduce efficiencies into trial timelines, overcoming such barriers is of critical importance. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B58.
Beyond superficial siderosis
Kumar, Neeraj

Mayo Clinic

Neurology | June 11, 2012 | Volume: 78 | Issue: 24 | Pages: 1992-1999

10.1212/wnl.0b013e318259e272 | PMID 22689736 Get It

Evaluation of pretransplant factors predicting cardiac dysfunction following high‐dose melphalan conditioning and autologous peripheral blood stem cell transplantation
Bleeker, Jonathan , Pellikka, Patricia A. , Dingli, David , Dispenzieri, Angela , Hayman, Suzanne R. , Kumar, Shaji , Rajkumar, S. Vincent , Lacy, Martha Q. , Gertz, Morie A. , Larson, Dirk R. , Buadi, Francis K. , Hogan, William J. , Rajkumar, S Vincent , Dispenzieri, Angela , Pellikka, Patricia A , Dingli, David

Mayo Clinic

European Journal of Haematology | June 1, 2012 | Volume: 89 | Issue: 3 | Pages: 228-235

10.1111/j.1600-0609.2012.01815.x | PMID 22672722 Get It

AbstractBackgroundCardiac complications following hematopoietic stem cell transplantation (HSCT) are emerging as a significant concern given the increasing utilization of HSCT for a variety of hematologic malignancies.MethodsWe utilized an existing database to determine the frequency of cardiac dysfunction (CD), namely a decrease in left ventricular ejection fraction, following conditioning with high‐dose melphalan (HDM) and autologous HSCT for multiple myeloma (MM) and systemic amyloidosis (AL). We then performed a case–control study to examine variables associated with increased risk of CD in this population.ResultsIn MM patients undergoing HSCT, the rate of CD was 1.6% (17/1050, 95% CI: [0.9, 2.6]). None of the examined pre‐HSCT variables or HDM dose were significantly associated with development of CD in this population. In patients with AL, the rate of CD was 5.6% (24/426, 95% CI: [3.6, 8.3]). On univariate analysis, decision to administer an HDM dose <200 mg/m2 [odds ratio (OR): 4.59 (1.27–16.57) P = 0.02], pretransplant left ventricular ejection fraction <60% [OR: 17.78 (2.29–138.33) P = 0.006], and documented amyloid involvement of ≥3 organs [OR: 4.0 (1.03–15.6) P = 0.046] were associated with the development of CD in the AL population. No other examined peri‐transplant factors were associated with development of CD.ConclusionTo our knowledge, this is the first series to report a significant rate of CD following HDM conditioning and autologous HSCT in patients with AL.
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
D’Souza, Anita , Lacy, Martha Q. , Kumar, Shaji , Hayman, Suzanne R. , Dingli, David , Zeldenrust, Steven R., Kyle, Robert A. , Ansell, Stephen M. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Porrata, Luis F. , Litzow, Mark R. , Gastineau, Dennis A., Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Hogan, William J. , D'Souza, Anita , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | May 20, 2012 | Volume: 120 | Issue: 1 | Pages: 56-62

10.1182/blood-2012-04-423178 | PMID 22611150 Get It

AbstractThe POEMS syndrome (polyradiculoneuropathy, organomegaly, multiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma cell dyscrasia. Patients with disseminated POEMS can be treated with high-dose therapy and autologous stem cell transplantation (ASCT). While clinical improvement is nearly universal in these patients, the long-term outcomes after transplantation are unclear. We therefore assessed the long-term clinical outcomes of 59 POEMS patients treated with ASCT at our institution. With a median follow-up of 45 months, 14 patients have progressed with a progression-free survival of 98% and 75% at 1 and 5 years, respectively. Factors associated with progression have included an IgG-λ monoclonal component (hazard ratio [HR] 7.5; 95% confidence interval [CI], 2.3-28.3; P = .0008), fluorodeoxyglucose-avid lesions on baseline positron emission tomography (HR 6.4; 95% CI, 1.2-120; P = .03), lack of complete hematologic response (HR 5.4; 95% CI, 1.8-16.7; P = .003), and patients aged 50 years or younger at transplantation (HR 4.4; 95% CI, 1.3-20; P = .01). The most common progression events have been radiologic followed by rising VEGF. Symptomatic progression has been rare. Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT.
Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration
Kumar, Neeraj , Gross, John B. , Ahlskog, J. Eric

Mayo Clinic

Neurology | May 13, 2012 | Volume: 63 | Issue: 1 | Pages: 33-39

10.1212/01.wnl.0000132644.52613.fa | PMID 15249607 Get It

Myelopathy due to copper deficiency
Kumar, Neeraj , Gross, John B. , Ahlskog, J. Eric

Mayo Clinic

Neurology | May 13, 2012 | Volume: 61 | Issue: 2 | Pages: 273-274

10.1212/01.wnl.0000073542.02761.5f | PMID 12874423 Get It